In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
A private share placement should see Regulus Therapeutics swell its coffers by around $100 million. 13 March 2024
Pharmaceutical
Spanish dermatology giant Almirall has entered into an agreement with USA-based Eloxx Pharmaceuticals related to the asset ZKN-013. 13 March 2024
Biotechnology
Privately-held US biotech IFM Therapeutics today announced that Swiss pharma giant Novartis has exercised its option to acquire all of the outstanding capital stock of its subsidiary, IFM Due. 13 March 2024
Generics
In what the company describes as “a significant stride towards making advanced cancer treatment accessible to all,” Indian drugmaker Zydus Lifesciences (NYSE: ZYDUSLIFE) has launched olaparib, a PARP inhibitor marketed by UK pharma major AstraZeneca (LSE: AZN) as Lynparza, under the brand name Ibyra in India. 13 March 2024
Biotechnology
Sweden-headquartered contract development and manufacturing organization (CDMO) Recipharm says that its ReciBioPharm unit has entered a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical US gene therapy company 13 March 2024
Biotechnology
Privately-held Dutch firm ProteoNic has announced a strategic alliance with US biotech Ginkgo Bioworks. 13 March 2024
Biotechnology
The biopharmaceutical industry is witnessing a shift in investor sentiment. Despite facing challenges such as declining venture financing and macroeconomic pressures, there exists optimism about a recovery in biotech funding. 13 March 2024
Pharmaceutical
Pfizer has won European Commission (EC) approval for Prevenar 20 for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in children aged from six weeks to less than 18 years. 13 March 2024
Biosimilars
Swiss generics and biosimilars major Sandoz today announced strong financial results for the fourth quarter and full year ended December 31, 2023. 13 March 2024
Biotechnology
Swiss drugmaker Roche - no doubt with the recent success of anti-amyloid candidates in mind - is persisting with its efforts in Alzheimer’s disease. 13 March 2024
Biotechnology
Cambridge, USA-based synthetic biology company Pearl Bio, which is backed by Khosla Ventures, has entered a license, collaboration and option agreement with pharma giant Merck & Co, to discover biologic therapies comprising non-standard amino acids. 13 March 2024
Biotechnology
US clinical stage biotech Coya Therapeutics’ shares closed down 7.7% at $9.01 yesterday, after it presented biomarker data as part of a panel presentation at the Society of Neuroimmune Pharmacology Conference. 13 March 2024
Pharmaceutical
French hearing specialist Sensorion has announced that a Phase IIa trial of SENS-401 has met its primary efficacy endpoint. 12 March 2024
Pharmaceutical
Following discussions with the US regulator, Texan drugmaker Lexicon Pharmaceuticals now plans to resubmit a New Drug Application (NDA) for sotagliflozin. 12 March 2024
Biotechnology
US pharma giant Pfizer today announced further positive data for its recently acquired Adcetris (brentuximab vedotin). 12 March 2024
Pharmaceutical
New Zealander Guy Oliver has left his role as Ipsen’s general manager for the UK and Ireland, to take up the same position at Bristol Myers Squibb. 12 March 2024
Biotechnology
US clinical-stage biotech IDRx today announced that it has strengthened its leadership team with the appointments of Tim Clackson, as chief executive and Brad Dahms as chief financial officer and chief business officer. 12 March 2024
Pharmaceutical
USA-based rare disease company Applied Therapeutics closed nearly 9% lower after Monday’s trading. 12 March 2024
Pharmaceutical
Swiss drugmaker Basilea Pharmaceutica announced yesterday that the continued strong sales performance of the antifungal Cresemba (isavuconazole) by its license partner Pfizer in the Asia Pacific region and China exceeded the sales threshold triggering a $1.25 million milestone payment. 12 March 2024
Pharmaceutical
Shares in San Diego, USA-based Acadia Pharmaceuticals fell around 20% ahead of the opening bell on Tuesday, following poor results from the ADVANCE-2 trial. 12 March 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze